Global Cannabis Price Trends: Q2 2025 — Germany vs. UK vs. Australia

Where Are Cannabis Prices Headed This Quarter?

As Q2 2025 unfolds, the global cannabis landscape continues to evolve rapidly. For international buyers and suppliers, staying ahead of price movements is key — especially in key medical markets like Germany, the United Kingdom, and Australia. At Leven, we’ve tracked wholesale pricing data, import trends, and buyer behavior to provide a snapshot of where prices are heading and what’s driving the shifts.

Leven presents their Global Price Trends

Germany: Stabilizing After Legalization Shockwaves

Germany remains the largest and most active importer of medical cannabis in Europe, but Q1’s recreational reform under CanG sent ripples through the supply chain.

• Price per gram (GMP flower): €2.00–€2.50

  
  

• Trend: Stable to slightly decreasing

  
  

• Reason: While adult-use legalization (Phase 1) drove consumer excitement, medical sales remained flat. Some buyers paused new orders to reassess demand forecasting.

  
  

• Forecast: With Phase 2 (cannabis clubs and regional pilot projects) looming, medical import volumes will likely hold steady, with slight downward pressure as more suppliers enter the German market post-GMP certification.

Leven Insight: Expect high demand for consistent, high-terpene EU-GMP flower, with growing price sensitivity among distributors.

Leven Approved Craft Flower for the Export Market

United Kingdom: Fragmented Market, Rising Buyer Leverage

The UK remains a fragmented but fast-growing medical cannabis market, with a widening gap between clinic buyers and pharmacy-based importers.

• Price per gram (GMP flower): £1.50–£2.80

• Trend: Softening

• Reason: An influx of product from Canada and Portugal has led to oversupply in certain SKUs, especially indica-heavy cultivars. New players are entering the market with aggressive pricing to win pharmacy contracts.

• Forecast: Prices are expected to drop 5–10% over the quarter as competition intensifies, especially in the 18–22% THC range.

Leven Insight: Clinic-owned supply chains are squeezing out smaller distributors. Differentiation in terpene profiles, minor cannabinoids, and vaporization readiness is becoming more valuable than just THC %.

Australia: Tight Supply, High Margins

Australia remains a high-margin market, but import controls and strict batch approvals continue to constrain volume.

• Price per gram (GMP flower): AUD $4.50

• Trend: Stable to increasing

• Reason: Delays in TGO 93 batch approvals and growing patient demand have created spot shortages, especially for niche cultivars and high-CBD strains.

• Forecast: Expect moderate price increases (~5%) through Q2, particularly for suppliers with strong local partnerships and seamless compliance packaging.

Leven Insight: Speed to market is king. Australian buyers are prioritizing suppliers who can navigate batch-specific import documentation with zero friction.

What This Means for Suppliers

Now is the time for flexible pricing strategies and localized differentiation. Buyers across all three markets are becoming more sophisticated — they’re not just looking for high-THC, they’re looking for value, compliance ease, consistency and patient retention power.

Leven is actively matching global suppliers with the right buyers across Germany, the UK, and Australia. With real-time pricing intelligence, document automation tools, and financing options, we’re helping partners close deals faster and more profitably.

To receive our monthly Leven Market Report with deal-by-deal pricing, trends, and insights, subscribe at leventherapeutics.com or reach out to our team.

Andrew Baukham - Leven Therapeutics.

Click to Subscribe - Access to all 7 issues - Leven Magazine

DISCLAIMER: The information provided in this article is for general informational purposes only and is not intended as legal advice. While we strive to provide accurate and up-to-date content, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability, or availability of the information presented in this article. Any reliance you place on such information is strictly at your own risk. We will not be liable for any losses or damages, including without limitation, indirect or consequential losses or damages, arising from the use of or reliance on this information. For specific legal advice, please consult with a qualified legal professional. By reading this article, you acknowledge and agree to this disclaimer.